GYRE 8-K

Gyre Therapeutics, Inc. (GYRE)

8-K 2026-08-07 For: 2026-08-07

View Original

Added on August 07, 2026


Delaware	000-51173	56-2020050
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


Exhibit Number		Exhibit Title or Description

99.1		Press Release, dated August 7, 2026

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


	GYRE THERAPEUTICS, INC.

Date: August 7, 2026	By:	/s/ Ying Luo
	Name:	Ying Luo
	Title:	Chief Executive Officer and President


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025 (As Recast)			2026			2025 (As Recast)
Revenues	$	29,105		$	29,734		$	53,535		$	60,305
Operating expenses:
Cost of revenues		2,209			1,151			3,436			2,045
Selling and marketing		13,754			15,195			27,890			26,035
Research and development		14,300			8,351			25,781			16,442
Research and development-related parties		4,836			—			4,836			—
General and administrative		7,867			7,277			18,043			15,481
Transaction costs		502			—			6,886			—
Total operating expenses		43,468			31,974			86,872			60,003
(Loss) income from operations		(14,363	)		(2,240	)		(33,337	)		302
Other (loss) income, net:
Interest income		740			941			1,483			1,797
Change in fair value of warrant liability		132			212			220			2,467
Other expense, net		(943	)		(488	)		(830	)		(301	)
(Loss) Income before income taxes		(14,434	)		(1,575	)		(32,464	)		4,265
Benefit (provision) for income taxes		164			(662	)		(385	)		(1,563	)
Net (loss) income		(14,270	)		(2,237	)		(32,849	)		2,702
Accretion of Cullgen redeemable convertible preferred stock		(1,058	)		(2,642	)		(3,905	)		(5,220	)
Net loss attributable to noncontrolling interest		(3,665	)		(2,835	)		(11,945	)		(2,644	)
Net (loss) income attributable to common stockholders	$	(11,663	)	$	(2,044	)	$	(24,809	)	$	126
Net (loss) income per share attributable to common stockholders:
Basic	$	(0.12	)	$	(0.02	)	$	(0.26	)	$	0.00
Diluted	$	(0.12	)	$	(0.03	)	$	(0.26	)	$	(0.03	)
Weighted average shares used in calculating net income per share attributable to common stockholders:
Basic		100,637,599			89,119,344			96,003,117			87,295,099
Diluted		100,637,599			89,203,138			96,003,117			87,430,167


	June 30, 2026			December 31, 2025
	(Unaudited)			(As Recast)
Assets
Current assets:
Cash and cash equivalents	$	43,287		$	49,192
Short-term bank deposits		14,058			15,355
Short-term investment		17,451			28,085
Notes receivable		232			5,638
Accounts receivables, net		27,760			31,078
Other receivables from GNI		255			230
Inventories, net		11,428			10,171
Prepaid assets and other current assets		7,601			9,613
Total current assets		122,072			149,362
Property and equipment, net		27,284			27,549
Intangible assets, net		4,525			4,727
Long-term prepayments		302			112
Deferred tax assets		9,284			6,873
Long-term certificates of deposit		28,444			23,516
Other assets, noncurrent		7,344			7,624
Total assets	$	199,255		$	219,763
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	1,236		$	1,335
Due to related parties		5,085			227
Accrued expenses and other current liabilities		18,810			18,161
Income tax payable		2,147			2,940
Operating lease liabilities, current		1,385			1,119
Total current liabilities		28,663			23,782
Operating lease liabilities, noncurrent		2,033			2,303
Deferred government grants		829			852
Warrant liability, noncurrent		2,741			2,961
Other noncurrent liabilities		70			1,506
Total liabilities		34,336			31,404
Commitments and Contingencies (Note 11)
Series B preferred stock, $0.001 par value, 5,000,000 shares authorized; 3,697,235 shares and zero shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		22,430			—
Redeemable convertible preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares and 2,601,826 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		—			15,784
Redeemable noncontrolling interests — Cullgen redeemable convertible preferred stock		—			113,030
Stockholders’ equity:
Common stock, $0.001 par value, 400,000,000 shares authorized; 106,033,763 shares and 91,314,007 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively		106			91
Additional paid-in capital		240,644			172,819
Statutory reserve		3,648			3,098
Accumulated deficit		(137,962	)		(112,603	)
Accumulated other comprehensive income (loss)		1,492			(908	)
Total Gyre stockholders’ equity		107,928			62,497
Noncontrolling interest		34,561			(2,952	)
Total equity		142,489			59,545
Total liabilities, Series B preferred stock, redeemable convertible preferred stock, and stockholders’ equity	$	199,255		$	219,763


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))